Skip to content

Clinical trials

Rheumatic Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Rheumatic Diseases Country / region: United States Clear all

68 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20031
20051
20061
20071
20081
20094
20103
20114
20121
20133
20142
20152
20164
20171
20183
20191
20204
20215
20225
20233
20246
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed38
Terminated11
Recruiting8
Active, not recruiting5
Unknown status3
Enrolling by invitation2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4
Novartis Pharmaceuticals4
University of Alabama at Birmingham4
National Institutes of Health Clinical Center (CC)3
Pfizer3
Regeneron Pharmaceuticals3
VA Office of Research and Development3
Amgen2
Anderson Orthopaedic Research Institute2
Brigham and Women's Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Rheumatic Diseases68
Arthritis30
Joint Diseases26
Musculoskeletal Diseases26
Osteoarthritis16
Arthritis, Rheumatoid15
Autoimmune Diseases13
Osteoarthritis, Knee10
Lupus Erythematosus, Systemic8
Gout7

Trials

Showing 1 to 25 of 68. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.